Skip to main content
. 2020 Dec 15;21(24):9558. doi: 10.3390/ijms21249558

Figure 4.

Figure 4

TGFβ1 serum levels. After 7 days, aflibercept significantly (p < 0.05) decreased TGFβ1 serum levels only in NPDR treated patients, compared to other study subject groups. * p < 0.05 vs. CTRL; ** p < 0.05 vs. diabetic patients without signs of DR; † p < 0.05 vs. NPDR naïve patients; ‡ p < 0.05 vs. NPDR either naïve or treated patients.